Neuronal nicotinic receptor inhibition for treating mood disorders: Preliminary controlled evidence with mecamylamine

Depression and Anxiety

Volumn 16, Issue 3, 2002, Pages 89-92

  Shytle, R Douglas ^a   Silver, Archie A ^a   Sheehan, Kathy H ^a   Sheehan, David V ^a   Sanberg, Paul R ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MECAMYLAMINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; PLACEBO;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; GILLES DE LA TOURETTE SYNDROME; HUMAN; HYPOMANIA; MAJOR DEPRESSION; MOOD DISORDER; MULTICENTER STUDY; OBSESSIVE COMPULSIVE DISORDER; OPPOSITIONAL DEFIANCE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SYMPTOM;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MECAMYLAMINE; NEURONS; NICOTINIC ANTAGONISTS; RECEPTORS, NICOTINIC; TOURETTE SYNDROME;

EID: 0036431617     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.10035     Document Type: Article

References (18)

1. Blomqvist O, Hernandez-Avila CA, Van Kirk J, Rose JE, Kranzler HR. 2002. Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcohol Clin Exp Res 26:326-331.
2. Covey LS, Glassman AH, Stetner F. 1998. Cigarette smoking and major depression. J Addict Dis 17:35-46.
3. Fryer JD, Lukas RJ. 1999. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J Neurochem 72:1117-1124.
4. Gadow KD, Sprafkin J. 1997. Child and adolescent symptom inventory 4: Norms Manuals. Stony Brook, NY: Checkmate Plus, Inc.
5. Hennings EC, Kiss JP, De Oliveira K, Toth PT, Vizi ES. 1999. Nicotinic acetylcholine receptor antagonistic activity of monoamine uptake blockers in rat hippocampal slices. J Neurochem 73:1043-1050.
6. Lukas RJ, Ke L, Bencherif M, Eisenhour CM. 1996. Regulation by nicotine of its own receptors. Drug Dev Res 38:136-148.
7. Papke RL, Sanberg PR, Shytle RD. 2001. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J Pharmacol Exp Ther 297:646-656.
8. Reid MS, Mickalian JD, Delucchi KL, Berger SP. 1999. A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects. Neuropsychopharmacology 20:297-307.
9. Rose JE, Behm FM, Westman EC. 1998. Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy. Exp Clin Psychopharmacol 6:331-343.
10. Sanberg PR, Shytle RD, Silver AA. 1998. Treatment of Tourette's syndrome with mecamylamine [letter]. Lancet 352:705-706.
11. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22-33.
12. Shytle R, Silver A, Lukas R, Newman M, Sheehan D, Sanberg P. 2001. Nicotinic acetylcholine receptors as targets for antidepressants. Molec Psychiatry. In press.
13. Sheehan D, Shytle RD, Newman M, Sanberg P, Silver AA. 1999. Development of the Tourette Disorder Scale (TODS). 39th Annual Meeting of the New Clinical Drug Evaluation Unit Program, Boca Raton, Florida.
14. Shytle RD, Silver AA, Sanberg PR. 2000. Comorbid bipolar disorder in Tourette syndrome responds to nicotinic receptor antagonist, mecamylamine (Inversine®). Biol Psychiatry 48:1028-1031.
15. Silver AA, Shytle RD, Sanberg PR. 2000. Mecamylamine in Tourette's syndrome: A two-year retrospective case. J Child Adolesc Psychopharmacol 10:59-68.
16. Silver AA, Shytle RD, Sheehan KH, Sheehan DV, Ramos A, Sanberg PR. 2001. Multi-center double blind placebo controlled study of mecamylamine monotherapy for Tourette's disorder. J Am Acad Child Adolesc Psychiatry 40:1103-1110.
17. Tizabi Y, Overstreet DH, Rezvani AH, Louis VA, Clark E, Jr., Janowsky DS, Kling MA. 1999. Antidepressant effects of nicotine in an animal model of depression. Psychopharmacology (Berl) 142:193-199.
18. Young JM, Shytle RD, Sanberg PR, George TP. 2001. Mecamylamine: New therapeutic uses and toxicity/risk profile. Clin Ther 23:532-565.